293
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Targeted Chemotherapy for Unresectable Primary and Metastatic Liver Cancer

, , , &
Pages 133-137 | Received 30 Jun 1993, Accepted 23 Aug 1993, Published online: 08 Jul 2009

References

  • Konno T, Maeda H, Yokoyama I. Use of a lipid lymphographic agent, Lipiodol, as a carrier of high molecular weight antitumor agent, SMANCS for hepatocellular carcinoma. Jpn J Cancer Chemother 1982; 9: 2005–15
  • Konno T, Maeda H, Iwai K. Effect of arterial administration of high-molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma. A preliminary report. Eur J Cancer Clin Oncol 1983; 19: 1053–65
  • Konno T, Maeda H, Iwai K. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumor by arterially administered lipid contrast medium. Cancer 1984; 54: 2367–74
  • Konno T. Targeting cancer chemotherapeutic agents by use of Lipiodol contrast medium. Cancer 1990; 66: 1897–903
  • Maeda H, Takeshita J, Kanamaru R. A lipophilic derivative of neocarzinostatin. Int J Pept Protein Res 1979; 14: 81–7
  • Maki S, Konno T, Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 1985; 56: 751–7
  • Konno T. Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol. Eur J Cancer 1992; 28: 403–9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.